Furthermore, the results of this systematic review stress on the importance of screening for bone metastases and reporting of clinical outcomes of treatment on bone metastases future trials for patients with EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.